Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms

Seminars in Nuclear Medicine

Volumn 42, Issue 3, 2012, Pages 190-207

  Baum, Richard P ^a   Kulkarni, Harshad R ^a   Carreras, Cecilia ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN ANTAGONIST; CONTRAST MEDIUM; COPPER 64; DEMOBESIN; DEPREOTIDE TC 99M; DOTANOC GA 68; DOTATATE GA 68; DOTATATE LUTETIUM 177; DOTATOC YTTRIUM 90; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; GALLIUM 68; IODINE; LUTETIUM 177; OCTREOTIDE; P829 TECHNETIUM 99M; PENTETREOTIDE IN 111; RADIOISOTOPE; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; UNCLASSIFIED DRUG; VAPREOTIDE TECHNETIUM 99M; YTTRIUM 90;

ADRENAL GLAND; ARTICLE; BRONCHUS CARCINOID; BRONCHUS TUMOR; CARCINOMA; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOCRINE TUMOR; ERYTHROPENIA; GASTROINTESTINAL TRACT; GLUCOSE METABOLISM; HUMAN; HYPOPHYSIS; IMAGE GUIDED RADIOTHERAPY; IN VIVO STUDY; LEUKOPENIA; LONG TERM CARE; LUNG SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MOLECULAR IMAGING; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE NEOPLASM; NEUROENDOCRINE TUMOR; NEUROTRANSMISSION; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PARAGANGLIOMA; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIATION EXPOSURE; RADIOACTIVITY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THYROID GLAND;

EID: 84859358363     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.01.002     Document Type: Review

References (98)

1. I.M. Modlin, K. Oberg, D.C. Chung Gastroenteropancreatic neuroendocrine tumors Lancet Oncol 9 2008 61 72
2. M. Anlauf, P. Gerlach, A. Raffel Neuroendocrine neoplasia of the gastroentero system Pathology and classification Onkologe 17 2011 572 582
3. J.A. Carrasquillo, C.C. Chen Molecular imaging of neuroendocrine tumors Semin Oncol 37 2010 662 679
4. A. Sundin, M.P. Vullierme, G. Kaltsas ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: Radiological examinations Neuroendocrinology 90 2009 167 183
5. E.P. Krenning, W.H. Bakker, W.A. Breeman Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin Lancet 1 1989 242 244
6. E.P. Krenning, W.H. Bakker, P.P. Kooij Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide J Nucl Med 33 1992 652 658
7. D. Wild, J.S. Schmitt, M. Ginj DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imaging 30 2003 1338 1347
8. J.C. Reubi, B. Waser, J.C. Schaer Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur J Nucl Med Mol Imaging 28 2001 836 846
9. R.T. Jensen Endocrine tumors of the gastrointestinal tract and pancreas D.L. Kasper, A.S. Fauci, D.L. Longo, Harrison's Principles of Internal Medicine (ed 16) 2005 McGraw-Hill New York
10. V. Rufini, M.L. Calcagni, R.P. Baum Imaging of neuroendocrine tumors Semin Nucl Med 36 2006 228 247
11. J.C. Reubi, J.C. Schar, B. Waser Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med Mol Imaging 27 2000 273 282
12. 123 I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients Eur J Nucl Med Mol Imaging 20 1993 716 731
13. 111 In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging Eur J Nucl Med Mol Imaging 37 2010 1441 1448
14. 111 In-pentetreotide scintigraphy J Nucl Med 43 2002 889 895
15. 111 In- octreotide J Nucl Med 41 2000 1114 1119
16. 99m Tc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumors: Synthesis and preclinical results Eur J Nucl Med Mol Imaging 29 2002 742 753
17. 111 In-DTPA0] octreotide: Does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 46 2005 1561 1569
18. P.M. Smith-Jones, B. Stolz, C. Bruns Gallium-67/gallium-68-[DFO]- octreotideA potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: Synthesis and radiolabeling in vitro and preliminary in vivo studies J Nucl Med 35 1994 317 325
19. M. de Jong, W.H. Bakker, E.P. Krenning Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy Eur J Nucl Med Mol Imaging 24 1997 368 371
20. A. Otte, J. Mueller-Brand, S. Dellas Yttrium-90-labelled somatostatin-analogue for cancer treatment Lancet 2 1998 417 418
21. 111 In-DTPAo]octreotide in patients Eur J Nucl Med 28 2001 1319 1325
22. M. Ginj, J. Chen, M.A. Walter Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy Clin Cancer Res 11 2005 1136 1145
23. 68 Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imaging 32 2005 724
24. V. Prasad, R.P. Baum Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: Characterization of uptake in normal organs and tumor lesions Q J Nucl Med Mol Imaging 54 2010 61 67
25. 68 Ga-labeled peptides in tumor imaging J Nucl Med 46 suppl 1 2005 172S 178S
26. D. Wild, M. Fani, M. Behe First clinical evidence that imaging with somatostatin receptor antagonists is feasible J Nucl Med 52 2011 1412 1417
27. F. Rsch, R.P. Baum Generator-based PET radiopharmaceuticals for molecular imaging of tumors: On the way to THERANOSTICS Dalton Trans 40 2011 6104 6111
28. K.P. Zhernosekov, D.V. Filosofov, R.P. Baum Processing of generator-produced 68Ga for medical application J Nucl Med 48 2007 1741 1748
29. 68 Ga-DOTA-TATE Eur J Nucl Med Mol Imaging 37 2010 2004 2010
30. R. Boellaard, M.J. O'Doherty, W.A. Weber FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0 Eur J Nucl Med Mol Imaging 37 2010 181 200
31. 68 Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: Correlation of sst2 mRNA and SUV max Eur J Nucl Med Mol Imaging 38 2011 1224 1236
32. 68 Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumors Eur J Nucl Med Mol Imaging 8 2011 1659 1668
33. 68 Ga-DOTATOC: Preliminary data Eur J Nucl Med Mol Imaging 28 2001 1751 1757
34. 111 In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumors Eur J Nucl Med Mol Imaging 34 2007 1617 1626
35. 68 Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 2007 508 518
36. 111 In]-DTPAOC SPECT First results in patients with neuroendocrine tumors Mol Imaging Biol 5 2003 42 48
37. 68 Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumors Eur J Nucl Med Mol Imaging 39 2012 72 82
38. 111 In-DTPA- octreotide (Octreoscan) Mol Imaging Biol 13 2011 583 593
39. 18 F-FDG PET/CT in pulmonary neuroendocrine tumors J Nucl Med 50 2009 1927 1932
40. D. Kaemmerer, K. Khatib-Chahidi, R.P. Baum Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT Cancer Imaging 11 2011 179 183
41. P. Antunes, M. Ginj, H. Zhang Are radiogallium-labeled DOTA-conjugated somatostatin analogues superior to those labeled with other radiometals? Eur J Nucl Med Mol Imaging 34 2007 982 993
42. 68 Ga DOTATATE PET/CT in functional imaging of neuroendocrine tumors J Nucl Med 52 2011 1864 1870
43. 111 In-DTPA-octreotide scintigraphy J Nucl Med 51 2010 875 882
44. 68 Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors J Nucl Med 51 2010 669 673
45. 90 Y-DOTATOC therapy Eur J Nucl Med Mol Imaging 33 2006 1115 1122
46. 123 I-MIBG in identifying malignant neural crest tumors Mol Imaging Biol 13 2011 769 775
47. G. Meisetschlger, T. Poethko, A. Stahl Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide J Nucl Med 47 2006 566 573
48. J.E. Sprague, Y. Peng, X. Sun Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator Clin Cancer Res 10 2004 8674 8682
49. C.J. Anderson, F. Dehdashti, P.D. Cutler 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors J Nucl Med 42 2001 213 221
50. 64 Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model Clin Cancer Res 5 1999 3608 3616
51. M. Wang, A.L. Caruano, M.R. Lewis Subcellular localization of radiolabeled somatostatin analogues: Implications for targeted radiotherapy of cancer Cancer Res 63 2003 6864 6869
52. V. Prasad, V. Ambrosini, M. Hommann Detection of unknown primary neuroendocrine tumors(CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT Eur J Nucl Med Mol Imaging 37 2010 67 77
53. 68 Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumors J Nucl Med 51 2010 353 359
54. H. Chalian, H.G. Tre, J.M. Horowitz Radiologic assessment of response to therapy: Comparison of RECIST versions 1.1 and 1.0 Radiographics 31 2011 2093 2105
55. R.P. Baum, V. Prasad, M. Hommann Receptor PET/CT imaging of neuroendocrine tumors Recent Results Cancer Res 170 2008 225 242
56. S. Adams, R.P. Baum, T. Rink Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors Eur J Nucl Med 25 1998 79 83
57. 18 F-FDG Cancer 112 2008 2447 2455
58. S. Oh, V. Prasad, D.S. Lee Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumorsintraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT Int J Mol Imaging 2011 2011 524130
59. 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors J Nucl Med 51 2010 1349 1356
60. E. Eldrup, N. Clausen, B. Scherling Evaluation of plasma 3,4 dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumour markers in children with neuroblastoma Scand J Clin Lab Invest 61 2001 479 490
61. 111 In-pentetreotide negative GEP tumours Nucl Med Commun 28 2007 473 477
62. R.P. Baum, V. Prasad PET and PET-CT imaging of neuroendocrine tumors R.L. Wahl, Principles and Practice of PET and PET/CT 2008 Lippincott Williams & Wilkins Philadelphia
63. J.C. Reubi, U. Horisberger, J.A. Laissue High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interactions? Int J Cancer 56 1994 681 688
64. J.C. Reubi, J.C. Schaer, J.A. Laissue Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels Metabolism 45 suppl 1 1996 39 41
65. D.J. Kwekkeboom, J. Mueller-Brand, G. Paganelli Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs J Nucl Med 46 suppl 1 2005 62S 66S
66. 90 Y-DOTATOC) in neuroendocrine tumors Eur J Nucl Med Mol Imaging 31 2004 1038 1046
67. 177 Lu-DOTA0, Tyr3]octreotate J Nucl Med 52 2011 1361 1368
68. 177 Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
69. A. Imhof, P. Brunner, N. Marincek Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers J Clin Oncol 29 2011 2416 2423
70. E.P. Krenning, P.P. Kooij, W.H. Bakker Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide A case history Ann N Y Acad Sci 733 1994 496 506
71. 177 Lu-DOTA(0), Tyr(3)-octreotate J Nucl Med 46 suppl 1 2005 83S 91S
72. A. Heppeler, S. Froidevaux, A.N. Eberle Receptor targeting for tumor localization and therapy with radiopeptides Curr Med Chem 7 2000 971 994
73. M.K. Moi, C.F. Meares The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane- N, N', N'',N'''-tetra-acetic acid and study of its yttrium(III) complex J Am Chem Soc 110 1988 6266 6267
74. S.V. Deshpande, S.J. DeNardo, D.L. Kukis Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent J Nucl Med 31 1990 473 479
75. A. Otte, E. Jermann, M. Behe DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy Eur J Nucl Med 24 1997 792 795
76. 3 -octreotide: Preliminary report in cancer patients Cancer Biother Radiopharm 14 1999 477 483
77. 3 ] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy Int J Cancer 75 1998 406 411
78. V. Prasad, D. Zachert, C. Hoersch Five year follow-up of renal function in neuroendocrine tumor patients treated with 5 or more cycles of peptide receptor radionuclide therapy (PRRNT) J Nucl Med 52 suppl 1 2011 299 (abstract)
79. R.P. Baum, J. Soeldner, M. Schmcking Clinical results of peptide receptor radionuclide therapy (PRRT) with yttrium-90-DOTA-TYR3-Octreotate (Y-90 DOTA-TATE) in patients with neuroendocrine tumors J Nucl Med 45 suppl 2004 90P (abstract)
80. D. Hrsch, V. Prasad, R.P. Baum Long term outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labeled somatostatin receptor targeting peptides J Clin Oncol 26 suppl 2008 4517 (abstract)
81. V. Prasad, R.P. Baum Comparison of renal function assessment using Tc-99m-DTPA (GFR), Tc-99m MAG3 (TER) and Cockcroft-Gault (CG-GFR) method in the long term follow-up of patients receiving more than 2 cycles of peptide receptor radionuclide therapy (PRRT) Eur J Nucl Med Mol Imaging 34 suppl 2 2007 S263 (abstract)
82. D. Kaemmerer, V. Prasad, W. Daffner Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor World J Gastroenterol 15 2009 5867 5870
83. A. Sowa-Staszczak, D. Pach, R. Chrzan Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NET) Eur J Nucl Med Mol Imaging 38 2011 1669 1674
84. 177 Lu-DOTATATE: Which is a better therapy option? Eur J Nucl Med Mol Imaging 38 2011 1788 1797
85. 177 Lu DOTA-NOC Cancer Biother Radiopharm 22 2007 406 416
86. H. Kulkarni, V. Prasad, C. Schuchardt Peptide receptor radionuclide therapy (PRRNT) of neuroendocrine tumors: Relationship between tumor dose and molecular response as measured by somatostatin receptor PET/CT J Nucl Med 52 suppl 1 2011 301 (abstract)
87. V. Prasad, H. Kulkarni, C. Zachert Safety and efficacy of peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumor patients having single kidney or nonfunctional kidney J Nucl Med 52 suppl 1 2011 1741 (abstract)
88. D. Hrsch, P. Grabowski, C.P. Schneider Current treatment options for neuroendocrine tumors Drugs Today 47 2011 773 786
89. J.C. Reubi, J.C. Schaer, B. Waser Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors Cancer Res 57 1997 1377 1386
90. R. Markwalder, J.C. Reubi Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation Cancer Res 59 1999 1152 1159
91. J.C. Reubi In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging J Nucl Med 36 1995 1846 1853
92. R.P. Schroeder, C. Mller, S. Reneman A standardised study to compare prostate cancer targeting efficacy of five radiolabeled bombesin analogues Eur J Nucl Med Mol Imaging 37 2010 1386 1396
93. T. Maina, B. Nock, R.P. Baum Radiolabeled GRPR-antagonists: New promising tools in the diagnosis and therapy of GRPR positive tumors World J Nucl Med 10 2011 26 59
94. von Guggenberg E, Rangger C, Sosabowski J, et al. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. Mol Imaging Biol (in press)
95. A.L. Tornesello, M. Aurilio, A. Accardo Gastrin and cholecystokinin peptide-based radiopharmaceuticals: An in vivo and in vitro comparison J Pept Sci 17 2011 405 412
96. D. Wild, A. Wicki, R. Mansi Exendin-4-based radiopharmaceuticals for glucagon like peptide-1 receptor PET/CT and SPECT/CT J Nucl Med 51 2010 1059 1067
97. 68 Ga-labeled exendin-3, a new agent for the detection of insulinomas with PET Eur J Nucl Med Mol Imaging 37 2010 1345 1355
98. 111 In-labeled DOTA-RGD peptides for imaging of alphav beta3 integrin expression Eur J Nucl Med Mol Imaging 35 2008 1507 1515